术前CT血管成像下腔静脉测量:经导管主动脉瓣植入术患者死亡率的预测因素
回顾性评估408例TAVI术前CTA患者,在205例有右心导管(RHC)的队列中,肝上段下腔静脉面积≥665 mm²预测1年死亡的特异度84%、敏感度63%,1年死亡率38% vs 7%(HR 5.5,95%CI 2.2-13.6);验证队列(203例)中该阈值下1年死亡率为34% vs 11%。
要点
- 肝上段下腔静脉面积≥665 mm²预测TAVI术后1年死亡,特异度84%、敏感度63%。
- IVC面积≥665 mm²组1年死亡率38%,<665 mm²组7%(log-rank P<0.001)。
- 验证队列中IVC面积≥665 mm²组1年死亡率34%,<665 mm²组11%(log-rank P=0.004)。
核心结论
- 术前肝上段下腔静脉扩张是TAVI评估患者术后1年死亡率的预测因素。
研究设计与样本
- 回顾性评估2011年1月至2014年12月间连续408例TAVI术前接受CTA的患者;205例在TAVI前≤1天内完成RHC和CTA者纳入RHC队列,另203例未满足该要求者纳入验证队列;在轴位图像上于膈肌与右心房之间测量下腔静脉,采用ROC分析、Kaplan-Meier分析和Cox回归分析。
关键影像表现/征象
- 下腔静脉扩张与TAVI患者右心功能障碍相关。
- 术前下腔静脉扩张可预测TAVI术后1年死亡率。
诊断标准与关键数值
- RHC队列中,IVC面积测量检测CVP≥10mmHg的AUC为0.77(P<0.001)。
- RHC队列中,IVC面积测量预测1年死亡率的AUC为0.72(P<0.001)。
- IVC面积截断值≥665 mm²预测1年死亡率,特异度84%、敏感度63%。
- RHC队列中,IVC面积≥665 mm²组1年死亡率38%,<665 mm²组7%(log-rank P<0.001),HR 5.5(95%CI 2.2-13.6;P<0.001)。
- 验证队列中,IVC面积≥665 mm²组1年死亡率34%,<665 mm²组11%(log-rank P=0.004)。
临床应用与阅片要点
- IVC测量对TAVI患者CVP升高具有中等预测价值。
- 术前IVC扩张可预测TAVI术后1年死亡率。
- IVC扩张与TAVI患者右心功能障碍相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To assess the value of pre-procedural computed tomography angiography (CTA) measurements of the suprahepatic inferior vena cava (IVC) to detect elevated central venous pressure (CVP) assessed by right heart catheterisation (RHC), and to predict post-procedural 1-year mortality in a cohort of patients undergoing transcatheter aortic valve implantation (TAVI).
METHODS: We retrospectively evaluated 408 consecutive patients undergoing CTA before TAVI between January 2011 and December 2014. Two hundred and five patients were included in the RHC cohort, who underwent RHC and CTA within ≤1 day prior to TAVI. Two hundred and three patients not fulfilling this requirement were included in the validation cohort. Measurements of the IVC were performed between diaphragm and right atrium on axial slices. Receiver operating characteristic (ROC) analyses, Kaplan-Meier analyses and Cox regression analyses were performed.
RESULTS: In the RHC cohort, ROC curve analyses for IVC area measurements indicated an AUC of 0.77 (p < 0.001) to detect CVP ≥10mmHg and an area under the ROC curve (AUC) of 0.72 (p < 0.001) to predict 1-year mortality. An IVC area cut-off of ≥665 mm2 predicted 1-year mortality with a specificity of 84% and a sensitivity of 63%. Kaplan-Meier analysis showed that patients with an IVC area ≥665 mm2 had a significantly higher post-procedural 1-year mortality (38% versus 7%, log-rank p < 0.001) with a hazard ratio of 5.5 (95% CI, 2.2-13.6; p < 0.001). Applying this cut-off value to the validation cohort confirmed a significantly higher 1-year mortality after TAVI (34% versus 11%; log-rank p = 0.004) for patients with an IVC area ≥665 mm2.
CONCLUSIONS: Pre-procedural enlargement of the suprahepatic IVC is a predictor of post-procedural 1-year mortality in patients evaluated for TAVI.
KEY POINTS: • IVC measurements are moderate predictors of an elevated CVP in TAVI patients. • Pre-procedural IVC enlargement is a predictor of 1-year mortality after TAVI. • IVC enlargement is associated with right heart dysfunction in TAVI patients.
引用
- Eberhard M, Milanese G, Ho M, et al. Pre-procedural CT angiography inferior vena cava measurements: a predictor of mortality in patients undergoing transcatheter aortic valve implantation. Eur Radiol. 2018. PMID: 30019141. doi:10.1007/s00330-018-5613-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。